Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 432 results for "Zohydro"

More on Zogenix Q2 results

Zogenix ( ZGNX ) Q2 results : Total Revenue: $9.2M (+3.4%), Zohydro Sales: $2.4M; Operating Loss: ($45.8M) (-314.0%); Net Income: $62.9M (+572.9%); EPS: $0.45 (+446.2%); Quick Assets: $81.2M (+12.8%). Zohydro ER prescriptions: 10,299. No specific ... Seeking Alpha, 2 weeks ago

160 images for Zohydro

WABC New York City, 2 weeks ago
WABC New York City, 2 weeks ago
Examiner.com, 1 month ago
Examiner.com, 1 month ago
Examiner.com, 1 month ago
Examiner.com, 1 month ago
WCVB.com, 1 month ago
WCVB.com, 1 month ago
SPi World News, 1 month ago
MedPage Today, 1 month ago
Mergers & Acquisitions

Zogenix (ZGNX) Receives Paragraph IV Notification on Zohydro ER ANDA

Visit StreetInsider.com at http://www.streetinsider.com/news.php-st=p&id=9757525 for the
 Wall Street Business Network6 days ago Zogenix Reports Second Quarter 2014 Financial Results  Vision Monday2 weeks ago Zohydro Gains Massachusetts Approval, Acts As Minor Catalyst For Zogenix  Benzinga.com2 weeks ago Struggling Drug Developer Zogenix Wins Massachusetts Lawsuit  Mergers & Acquisitions4 weeks ago
[x]  

Despite The Sell-Off, Zohydro Is A Falling Knife Too Dangerous To Catch

Summary Zohydro will stay on the market after multiple clear signals from the FDA standing by its approval. The real question is if doctors will prescribe the drug given the crowded space with multiple generics options. I spoke with 2 physicians, ...
 Seeking Alpha4 weeks ago
WCVB.com

Judge blocks Massachusetts painkiller restriction

BOSTON -- Massachusetts must temporarily suspend one of its key restrictions on Zohydro, a powerful new prescription painkiller, pending the outcome of a lawsuit challenging their constitutionality, a federal judge ruled on Tuesday. U.S. District ...
 Miami Herald1 month ago
[x]  
Bidness Etc

Purdue pain pill gets priority review

The FDA grants Priority Review to Purdue for its tamper-resistant pain medication that competes with Zogenix's ( ZGNX ) Zohydro. The agency's review of the company's hydrocodone tablet should take ~six months. Purdue's chronic pain offering is hard ...
 Seeking Alpha1 month ago Why Zogeniz (ZGNX) Stock Is Tumbling Today  TheStreet.com1 month ago Zogenix Falls On Speculation That Its Drug Will Be Taken Off Market  Bidness Etc1 month ago Purdue's Abuse-Resistant Pill Gets FDA Priority Review  Bloomberg1 month ago

What If The Figure That Justifies Zohydro's Existence Is Fake?

When the Food and Drug Administration defended its decision to approve Zohydro, a narcotic pill made by Zogenix that, unlike competitors, is not abuse resistant, it fell back on a number from the prestigious Institute of Medicine: 100 million people ...
 Forbes.com1 month ago What If The Figure Justifying Zohydro's Existence Is Fake?  Forbes.com1 month ago
BusinessWeek

How to Sell the Prescription Painkiller Politicians Fear

Few drugs in recent memory have caused an uproar like the new prescription painkiller Zohydro. The company behind it, San Diego-based Zogenix, says it's an advance in pain treatment. Critics warn that it could feed the country's epidemic of ...
 BusinessWeek1 month ago My Sister Died of an Overdose of Prescription Painkillers  Huffington Post1 week ago Prescription painkiller overdoses continue to skyrocket  CBS News2 weeks ago Popping Pills in America: Can the DEA Fix This?  Drugs.com1 month ago

Zogenix Provides Update on Zohydro(R) ER; Isis Pharma Earns $1M From GSK Hepatitis B Virus Program

Below is a look at some of the headlines for companies that made news in the healthcare sector on July 2, 2014. Zogenix, Inc. (ZGNX) announced an update on its development programs focused on the introduction of abuse deterrent formulations ...
 BioMedReports1 month ago Regeneron, Sanofi Offer Positive Results from Phase 2b of Dupilum; Celgene's Drug OTEZLA Fails Phase III Trial Endpoint  HispanicBusiness.com3 weeks ago
[x]  

Zogenix seeks partner, steers Zohydro marketing away from weak New England

Marketing can be a bit like dating. If you're not getting results with one target, then it's best to focus on someone else. That's exactly what Zogenix ($ZGNX) is doing, by tweaking its Zohydro launch strategy. The controversial new ...
 FiercePharma2 weeks ago Zogenix seeks partner steers Zohydro marketing away from weak New England  Big News Network2 weeks ago

Sector Update: Healthcare

If approved, the new tablets should be on the market early next year, ZGNX said. Zohydro has been critized by anti-drug abuse advocates because its current formulation does not have deterrents intended to keep individuals from crushing and then ...
 Nasdaq1 month ago Sector Update: Health Care Stocks Mixed; Zogenix Finding Investor Support After Turning Q2 Profit  Nasdaq2 weeks ago Sector Update: Health-Care Shares Mixed Pre-Market; TherapeuticsMD Surges 25% on Initiated Analyst Coverage  Nasdaq1 month ago Sector Update: Health Care  Nasdaq1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less